Last 27 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.02 | 18.78 | 19.21 | 16.19 | 7.95 | 2.51 | 1.54 | 1.52 | 1.07 | 0.86 | 0.56 | 0.37 | — | 82.60 | 82.18 | 58.99 | 139.83 | 73.31 | 66.63 | 194.98 | 289.03 |
| — | +646.7% | +1144.4% | +964.9% | +644.1% | +194.1% | +175.8% | +308.0% | — | -99.0% | -99.3% | -99.4% | — | +12.7% | +23.3% | -69.7% | -51.6% | +0.8% | -15.7% | +154.4% | — | |
| P/B Ratio | 0.59 | 1.83 | 2.12 | 1.61 | 2.04 | 0.14 | 0.15 | 0.14 | 0.12 | 0.10 | 0.07 | 0.27 | 20.68 | 7.47 | 6.33 | 3.44 | 3.30 | 3.16 | 4.23 | 8.41 | 6.45 |
| — | +1226.2% | +1275.1% | +1090.9% | +1637.1% | +34.0% | +119.4% | -49.7% | -99.4% | -98.6% | -98.9% | -92.2% | +526.6% | +136.7% | +49.8% | -59.1% | -48.8% | +4.5% | -32.6% | +93.4% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.0% | 61.7% | 63.4% | 66.3% | 70.4% | 91.2% | 46.2% | 72.2% | 87.9% | 88.2% | 73.5% | 60.0% | -3.2% | 36.0% | 42.9% | 14.7% | -45.5% | 34.7% | 34.3% | 44.6% | 33.0% |
| — | -32.3% | +37.3% | -8.1% | -19.9% | +3.4% | -37.1% | +20.2% | +2868.7% | +145.1% | +71.5% | +308.2% | +93.0% | +3.7% | +24.8% | -67.0% | -237.7% | -50.9% | -19.3% | +12.5% | -26.4% | |
| Operating Margin | -1942.2% | -6258.3% | -2150.2% | -1199.7% | -1479.2% | -5335.8% | -1707.9% | -1359.8% | -710.0% | -601.4% | -747.9% | -746.4% | -8634.9% | -3440.7% | -2632.3% | -1981.5% | -4331.4% | -1957.4% | -905.8% | -917.3% | -1929.2% |
| — | -17.3% | -25.9% | +11.8% | -108.3% | -787.2% | -128.4% | -82.2% | +91.8% | +82.5% | +71.6% | +62.3% | -99.4% | -75.8% | -190.6% | -116.0% | -124.5% | +7.4% | +12.5% | +0.3% | -1545.6% | |
| Net Margin | -1893.6% | -5334.8% | -2116.0% | -1189.9% | -1491.5% | -5270.8% | -1591.1% | -1315.2% | -676.8% | -571.7% | -729.3% | -740.5% | -9568.3% | -3404.0% | -2595.4% | -1952.5% | -3683.5% | -1978.9% | -1206.9% | -948.6% | -1946.9% |
| — | -1.2% | -33.0% | +9.5% | -120.4% | -822.0% | -118.2% | -77.6% | +92.9% | +83.2% | +71.9% | +62.1% | -159.8% | -72.0% | -115.1% | -105.8% | -89.2% | +5.4% | -17.8% | -14.7% | -1594.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.7% | -81.2% | -46.0% | -43.6% | -69.6% | -63.8% | -33.7% | -25.7% | -17.2% | -21.8% | -38.0% | -83.0% | -90.2% | -57.1% | -40.8% | -25.2% | -19.8% | -19.4% | -17.7% | -9.8% | -13.6% |
| — | -27.2% | -36.3% | -70.0% | -305.2% | -192.8% | +11.3% | +69.1% | +80.9% | +61.8% | +6.9% | -228.7% | -356.3% | -193.8% | -131.2% | -158.0% | -45.1% | +6.0% | +9.9% | +55.3% | +73.6% | |
| ROA | -126.8% | -44.6% | -33.1% | -30.1% | -42.2% | -44.7% | -26.7% | -21.6% | -14.7% | -17.9% | -23.5% | -37.3% | -50.9% | -35.6% | -29.0% | -18.9% | -15.4% | -15.9% | -15.1% | -8.6% | -11.6% |
| — | +0.2% | -23.7% | -39.4% | -186.6% | -149.4% | -14.0% | +42.1% | +71.1% | +49.6% | +19.0% | -97.4% | -230.5% | -123.2% | -91.8% | -120.4% | -32.2% | +6.5% | +6.1% | +42.6% | +18.2% | |
| ROIC | -588.1% | — | -481.4% | -250.9% | -228.6% | -212.2% | -106.7% | -94.5% | -75.1% | -79.9% | -72.1% | -89.8% | -76.4% | -43.8% | -34.8% | -26.8% | -29.8% | -30.1% | -23.3% | -16.9% | -19.5% |
| — | — | -351.2% | -165.6% | -204.3% | -165.7% | -48.0% | -5.2% | +1.7% | -82.5% | -107.4% | -235.3% | -156.4% | -45.2% | -49.5% | -58.5% | -52.5% | -12.2% | +47.6% | +64.1% | -8.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.09 | 0.06 | 0.05 | 0.15 | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 | 0.12 | 0.62 | 0.30 | 0.33 | 0.21 | 0.15 | 0.13 | 0.11 | 0.10 | 0.09 | 0.08 |
| — | -11.3% | -38.0% | -38.2% | +119.6% | +58.1% | -23.2% | -87.9% | -78.2% | -81.1% | -43.2% | +312.6% | +138.3% | +195.8% | +111.0% | +72.2% | +51.5% | -27.3% | -32.1% | -37.1% | -96.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.33 | 1.25 | 2.63 | 3.88 | 1.33 | 2.09 | 3.43 | 5.61 | 7.60 | 7.67 | 4.18 | 0.71 | 1.50 | 1.49 | 2.52 | 4.14 | 4.17 | 6.25 | 7.80 | 13.28 | 13.06 |
| — | -40.4% | -23.4% | -30.8% | -82.5% | -72.7% | -17.9% | +690.3% | +405.4% | +415.9% | +65.7% | -82.8% | -63.9% | -76.2% | -67.7% | -68.8% | -68.1% | -38.5% | -22.9% | +46.0% | +2606.3% | |
| Quick Ratio | 1.33 | 1.25 | 2.63 | 3.88 | 1.33 | 2.09 | 3.43 | 5.61 | 7.60 | 7.67 | 4.18 | 0.71 | 1.50 | 1.49 | 2.52 | 4.14 | 4.17 | 6.25 | 7.80 | 13.28 | 13.06 |
| — | -40.4% | -23.4% | -30.8% | -82.5% | -72.7% | -17.9% | +690.3% | +405.4% | +415.9% | +65.7% | -82.8% | -63.9% | -76.2% | -67.7% | -68.8% | -68.1% | -38.5% | -22.9% | +46.0% | +2606.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -4068.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LGVN stock.
Longeveron Inc.'s current P/E is -0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Longeveron Inc.'s current operating margin is -1942.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Longeveron Inc.'s business trajectory between earnings reports.